You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 2, February 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (22)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Otolaryngology/ Head & Neck Surgery
 •Dermatologic Disorders
 •Laryngology/ Speech/ Language Pathology
 •Bullous Diseases
 •Pemphigoid
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Anti-Epiligrin Cicatricial Pemphigoid With Antibodies Against the {gamma}2 Subunit of Laminin 5

Hossein C. Nousari, MD; Adrienne Rencic, MD, PhD; Roger Hsu, MD; Kim B. Yancey, MD; Grant J. Anhalt, MD

Arch Dermatol. 1999;135:173-176.

Background  Cicatricial pemphigoid (CP) is a scarring subepithelial mucocutaneous blistering disease characterized by anti–basement membrane zone autoantibodies. Anti-epiligrin CP is an uncommon variant that has been recently characterized. Severe laryngeal involvement is infrequently observed in all forms of CP and has been documented in only 2 patients with anti-epiligrin CP.

Observations  We report a case of CP exhibiting extensive laryngeal and ocular involvement. Histological, immunofluorescence, and immunoprecipitation studies confirmed the diagnosis of anti-epiligrin CP. Immunoblotting studies demonstrated the presence of antibodies against the {alpha}3 and the {gamma}2 subunit of laminin 5.

Conclusion  This article expands the diversity of the clinical and immunopathologic features of this newly characterized variant of CP.


From the Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore (Drs Nousari, Rencic, Hsu, and Anhalt) and the Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda (Dr Yancey), Md.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(2):226-227.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The First International Consensus on Mucous Membrane Pemphigoid: Definition, Diagnostic Criteria, Pathogenic Factors, Medical Treatment, and Prognostic Indicators
Chan et al.
Arch Dermatol 2002;138:370-379.
ABSTRACT | FULL TEXT  

Identification of Ocular Cicatricial Pemphigoid Antibody Binding Site(s) in Human {beta}4 Integrin
Kumari et al.
IOVS 2001;42:379-385.
ABSTRACT | FULL TEXT  

Autoantibodies against the Processed Ectodomain of Collagen XVII (BPAG2, BP180) Define a Canine Homologue of Linear IgA Disease of Humans
Olivry et al.
Vet Pathol 2000;37:302-309.
ABSTRACT | FULL TEXT  

Inflammatory Variant of Epidermolysis Bullosa Acquisita With IgG Autoantibodies Against Type VII Collagen and Laminin {alpha}3
Jonkman et al.
Arch Dermatol 2000;136:227-231.
ABSTRACT | FULL TEXT  

Antiepiligrin Cicatricial Pemphigoid: An Underdiagnosed Entity Within the Spectrum of Scarring Autoimmune Subepidermal Bullous Diseases?
Leverkus et al.
Arch Dermatol 1999;135:1091-1098.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.